Grace Therapeutics, Inc. (GRCE) stock
GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
$1.81−0.04 (-2.43%)
Close on Nov 12, 2026Market cap $38.08MP/E –Yield –
Grace Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Grace Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.46M, down 54.0% year over year. For fiscal 2026 it was $2.41M, down 74.7% from the year before. The highest annual figure on record is $29.37M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $2.41M | -74.7% |
| FY2025 | Mar 31, 2025 | $9.51M | +103.1% |
| FY2024 | Mar 31, 2024 | $4.68M | -53.0% |
| FY2023 | Mar 31, 2023 | $9.97M | +79.4% |
| FY2022 | Mar 31, 2022 | $5.56M | +33.2% |
| FY2021 | Mar 31, 2021 | $4.17M | -73.9% |
| FY2020 | Mar 31, 2020 | $15.97M | -45.6% |
| FY2019 | Mar 31, 2019 | $29.37M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | $885.00K | +55.8% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $697.00K | -27.0% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $420.00K | -74.3% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $462.00K | -78.9% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $568.00K | -80.9% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $955.00K | -64.7% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $1.63M | -3.0% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $2.19M | +52.0% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $2.98M | +547.0% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $2.71M | +147.3% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $1.69M | +2.7% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $1.44M | -41.1% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $460.00K | -86.0% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $1.10M | -57.7% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $1.64M | -29.5% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $2.45M | +12.4% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $3.29M | +462.7% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $2.59M | +452.2% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $2.33M | +413.5% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $2.18M | +221.4% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $585.00K | -54.5% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $469.00K | -73.3% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $453.00K | -76.4% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $678.00K | -82.7% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $1.29M | -67.5% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $1.76M | -71.6% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $1.92M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $3.91M | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $3.95M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $6.19M | – |
See a number that looks wrong?